---
title: "Teriparatide"
canonical_url: https://peptidelibrary.app/library/teriparatide
description: "FDA-approved PTH(1–34) anabolic agent (Forteo/Bonsity) for osteoporosis at high fracture risk."
updated: 2026-11-07
publisher: Peptide Library
notice: "Research and educational use only. Not medical advice."
---

# Teriparatide

Teriparatide (also called Forteo or Bonsity) is a research peptide in the PTH1 receptor agonist class. Teriparatide is recombinant human parathyroid hormone(1-34), the N-terminal fragment that carries the receptor-binding activity of the full hormone. It acts at the PTH1 receptor on osteoblasts.

FDA-approved PTH(1–34) anabolic agent (Forteo/Bonsity) for osteoporosis at high fracture risk.

Also known as: Forteo, Bonsity, PTH (1-34).

Categories: Muscle/Recovery.

## Classification

- Type: FDA-approved PTH(1-34)
- Mechanism class: PTH1 receptor agonist
- Development stage: Approved product
- Regulatory class: FDA-approved medicine

## Mechanism

Teriparatide is recombinant human parathyroid hormone(1-34), the N-terminal fragment that carries the receptor-binding activity of the full hormone. It acts at the PTH1 receptor on osteoblasts. The critical variable is exposure pattern rather than dose: continuous elevation of parathyroid hormone, as in hyperparathyroidism, favours RANKL-driven osteoclastic resorption and net bone loss, whereas brief daily peaks increase osteoblast number and survival and produce net bone formation. Intermittent once-daily dosing exploits that anabolic window. It is one of the few osteoporosis treatments that builds new bone rather than inhibiting its removal, and the effect declines after treatment stops unless followed by an antiresorptive.

Targets: PTH1 receptor.

Origin: Recombinant PTH(1–34).

## Properties

- Molecular formula: C181H291N55O51S2
- Molecular weight: 4,117.8 g/mol
- CAS number: 52232-67-4
- Half-life: About 1 hour after subcutaneous injection (Forteo label)
- Studied routes: Subcutaneous

## Evidence

- Evidence level: FDA Approved
- Highest documented: Regulatory review (FDA label)
- Human trials: 1
- Controlled human trials: 1
- Preclinical sources: 0
- Latest source: 2010

Each step shows whether the sources Peptide Library has reviewed include that kind of research. Counts are reviewed sources, not every study ever published. Reviews and programme summaries that describe human use are shown as "reported", not as trials, and registered trials without published results are listed but not counted. A higher step means research has progressed further; it does not mean a compound works better or is safer. Compounds whose evidence has not been reviewed yet show "Not reviewed" instead of a guess.

### Studies

1. FORTEO (teriparatide injection) — FDA prescribing information, DailyMed. Regulatory label (FDA), human. Population: Postmenopausal women with osteoporosis at high risk for fracture; men with primary or hypogonadal osteoporosis at high risk; men and women with glucocorticoid-induced osteoporosis at high risk [Source](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aae667c5-381f-4f92-93df-2ed6158d07b0)
2. Teriparatide Injection (Teva) — FDA prescribing information, DailyMed. Regulatory label (FDA), human. Population: The same three osteoporosis populations as Forteo. Treatment of osteoporosis [Source](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d371f0f7-d492-4481-b360-051456d56d65)
3. BONSITY (teriparatide injection) — FDA prescribing information, DailyMed. Regulatory label (FDA), human. Population: The same osteoporosis populations as Forteo. Treatment of osteoporosis [Source](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2d0c89a2-3849-adf6-007d-aeca21cf417c)
4. Aspenberg P et al. Teriparatide for acceleration of fracture repair in humans: a prospective, randomized, double-blind study of 102 postmenopausal women with distal radial fractures. J Bone Miner Res. 2010. 2010. Controlled human trial. Population: Postmenopausal women aged 45 to 85 with a distal radial fracture treated by closed reduction without surgery (n=102) [Source](https://pubmed.ncbi.nlm.nih.gov/19594305/)

## Safety

Side effects: Hypercalcemia; Nausea; Leg cramps; Orthostasis.

Risks: Osteosarcoma boxed warning (animal); Lifetime duration cap.

Human safety basis: FDA prescribing information

## Regulatory status

Teriparatide is an FDA-approved product for specific labelled indications. Approval does not extend to the research contexts described on this page, and approved products are prescription medicines.

- FDA status: Approved
- WADA status: Permitted
- Availability: Prescription-Only

## Frequently asked questions

### What is Teriparatide?

FDA-approved PTH(1–34) anabolic agent (Forteo/Bonsity) for osteoporosis at high fracture risk.

### How does Teriparatide work?

Teriparatide is recombinant human parathyroid hormone(1-34), the N-terminal fragment that carries the receptor-binding activity of the full hormone. It acts at the PTH1 receptor on osteoblasts.

### Is Teriparatide FDA approved?

Yes. Teriparatide is approved by the FDA, and approved products are prescription medicines. Approval is always for specific indications studied in clinical trials, so an approved status does not mean the compound is approved for every use it is discussed for. Research-chemical material sold under the same name is not the approved product.

### What is the half-life of Teriparatide?

Reported half-life for Teriparatide is ~1 hour (sc). Half-life describes how long the compound persists in circulation, not how long any effect lasts, and published figures vary with route of administration, formulation and the population studied.

### Is Teriparatide banned in sport?

Teriparatide is recorded here as permitted in sport. Anti-doping status is revised annually, so athletes subject to testing should confirm against the current WADA Prohibited List before use.

### What peptides are similar to Teriparatide?

Compounds most often compared with Teriparatide include Abaloparatide, PTH(1-34) Analog (Generic Teriparatide) and Bivalirudin. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.

## References

- [FDA label — Forteo](https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021318s053lbl.pdf)
- [Efficacy and safety of teriparatide vs. bisphosphonates and denosumab vs. bisphosphonates in osteoporosis not previously treated with bisphosphonates: a systematic review and meta-analysis of randomized controlled trials — Arch Osteoporos, 2024](https://pubmed.ncbi.nlm.nih.gov/39312040/)
- [Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial — Lancet, 2015](https://pubmed.ncbi.nlm.nih.gov/26144908/)
- [PTH1 receptor agonists for fracture risk: a systematic review and network meta-analysis — Osteoporos Int, 2025](https://pubmed.ncbi.nlm.nih.gov/40047881/)
- [Teriparatide (forteo) for osteoporsis — Med Lett Drugs Ther, 2003](https://pubmed.ncbi.nlm.nih.gov/12571538/)
- [Off-Label Use of Teriparatide in Spine — Cureus, 2021](https://pubmed.ncbi.nlm.nih.gov/34430132/)

Note: Dose figures are left out of this Markdown version. See the cited sources.
